| 0 |
CEREBRAL CANDIDIASIS |
10 |
0.6667 |
| 1 |
GEMELLA BACTERAEMIA |
1 |
0.5000 |
| 2 |
CHEMOTHERAPEUTIC DRUG LEVEL BELOW THERAPEUTIC |
2 |
0.1333 |
| 3 |
CHEMOTHERAPEUTIC DRUG LEVEL DECREASED |
1 |
0.0909 |
| 4 |
STOMATOCOCCAL INFECTION |
9 |
0.0726 |
| 5 |
BASAL GANGLIA HAEMATOMA |
2 |
0.0476 |
| 6 |
ENZYME ACTIVITY DECREASED |
1 |
0.0455 |
| 7 |
RESPIRATORY MONILIASIS |
10 |
0.0373 |
| 8 |
ASPERGILLUS TEST |
1 |
0.0256 |
| 9 |
OPTIC NERVE SHEATH HAEMORRHAGE |
2 |
0.0244 |
| 10 |
PARAINFLUENZA VIRUS INFECTION |
2 |
0.0194 |
| 11 |
SKIN CANDIDA |
10 |
0.0192 |
| 12 |
HYPERINSULINISM |
2 |
0.0187 |
| 13 |
ANTITHROMBIN III DEFICIENCY |
1 |
0.0112 |
| 14 |
ENZYME INHIBITION |
1 |
0.0104 |
| 15 |
ENTEROBACTER TEST POSITIVE |
2 |
0.0081 |
| 16 |
CULTURE WOUND POSITIVE |
2 |
0.0077 |
| 17 |
LYMPHOID TISSUE HYPOPLASIA |
1 |
0.0065 |
| 18 |
HYPERAMMONAEMIA |
31 |
0.0062 |
| 19 |
SUBGALEAL HAEMATOMA |
1 |
0.0060 |
| 20 |
THYMUS HYPOPLASIA |
1 |
0.0057 |
| 21 |
HUMAN BOCAVIRUS INFECTION |
1 |
0.0053 |
| 22 |
EYE INFECTION FUNGAL |
2 |
0.0052 |
| 23 |
SUPERIOR SAGITTAL SINUS THROMBOSIS |
4 |
0.0050 |
| 24 |
AMMONIA ABNORMAL |
2 |
0.0050 |
| 25 |
T-CELL TYPE ACUTE LEUKAEMIA |
1 |
0.0049 |
| 26 |
DRUG CLEARANCE INCREASED |
1 |
0.0045 |
| 27 |
SYSTEMIC CANDIDA |
11 |
0.0044 |
| 28 |
NOROVIRUS TEST POSITIVE |
1 |
0.0031 |
| 29 |
ADMINISTRATION SITE SWELLING |
1 |
0.0031 |
| 30 |
ESCHERICHIA BACTERAEMIA |
7 |
0.0030 |
| 31 |
CYSTITIS BACTERIAL |
1 |
0.0030 |
| 32 |
CEREBRAL MASS EFFECT |
1 |
0.0028 |
| 33 |
ABSCESS BACTERIAL |
1 |
0.0028 |
| 34 |
ANISOCORIA |
1 |
0.0026 |
| 35 |
ADMINISTRATION SITE REACTION |
1 |
0.0026 |
| 36 |
THERAPEUTIC PRODUCT EFFECT INCREASED |
3 |
0.0026 |
| 37 |
SECONDARY IMMUNODEFICIENCY |
3 |
0.0025 |
| 38 |
AMMONIA INCREASED |
12 |
0.0023 |
| 39 |
MINIMAL RESIDUAL DISEASE |
1 |
0.0021 |
| 40 |
SEPSIS SYNDROME |
1 |
0.0020 |
| 41 |
INADEQUATE DIET |
1 |
0.0019 |
| 42 |
PRODUCT CLOSURE ISSUE |
1 |
0.0018 |
| 43 |
PANCREATITIS NECROTISING |
4 |
0.0017 |
| 44 |
HYPERAMMONAEMIC ENCEPHALOPATHY |
3 |
0.0017 |
| 45 |
HERPES SIMPLEX |
11 |
0.0017 |
| 46 |
ESCHERICHIA TEST POSITIVE |
2 |
0.0017 |
| 47 |
CEREBRAL ASPERGILLOSIS |
1 |
0.0016 |
| 48 |
HEPATOBILIARY DISEASE |
1 |
0.0016 |
| 49 |
VASOGENIC CEREBRAL OEDEMA |
1 |
0.0014 |
| 50 |
MYCOBACTERIUM CHELONAE INFECTION |
1 |
0.0014 |
| 51 |
CEREBRAL VENOUS SINUS THROMBOSIS |
1 |
0.0012 |
| 52 |
ENTEROVIRUS INFECTION |
1 |
0.0012 |
| 53 |
TREATMENT DELAYED |
2 |
0.0012 |
| 54 |
PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT |
1 |
0.0011 |
| 55 |
PSEUDOMONAL SEPSIS |
2 |
0.0011 |
| 56 |
HYPOFIBRINOGENAEMIA |
1 |
0.0010 |
| 57 |
IMMEDIATE POST-INJECTION REACTION |
1 |
0.0009 |
| 58 |
DIFFUSE ALVEOLAR DAMAGE |
1 |
0.0009 |
| 59 |
NECROTISING FASCIITIS |
3 |
0.0009 |
| 60 |
WHITE MATTER LESION |
1 |
0.0008 |
| 61 |
PLATELET TRANSFUSION |
1 |
0.0008 |
| 62 |
DRUG LEVEL BELOW THERAPEUTIC |
4 |
0.0007 |
| 63 |
VIRAEMIA |
1 |
0.0007 |
| 64 |
BLOOD CULTURE POSITIVE |
2 |
0.0007 |
| 65 |
ANTIBODY TEST POSITIVE |
1 |
0.0006 |
| 66 |
ENTEROBACTER INFECTION |
1 |
0.0006 |
| 67 |
INJECTION SITE CELLULITIS |
1 |
0.0005 |
| 68 |
HUMAN HERPESVIRUS 6 INFECTION |
1 |
0.0005 |
| 69 |
BLOOD BICARBONATE DECREASED |
1 |
0.0005 |
| 70 |
RHINOVIRUS INFECTION |
2 |
0.0005 |
| 71 |
CYTOMEGALOVIRUS CHORIORETINITIS |
1 |
0.0005 |
| 72 |
HYPERTRIGLYCERIDAEMIA |
3 |
0.0005 |
| 73 |
FEBRILE NEUTROPENIA |
28 |
0.0004 |
| 74 |
VENOOCCLUSIVE LIVER DISEASE |
2 |
0.0004 |
| 75 |
VENOOCCLUSIVE DISEASE |
1 |
0.0004 |
| 76 |
PANCREATITIS |
20 |
0.0004 |
| 77 |
SUBDURAL HAEMORRHAGE |
1 |
0.0004 |
| 78 |
RASH MORBILLIFORM |
1 |
0.0004 |
| 79 |
CEREBRAL THROMBOSIS |
1 |
0.0004 |
| 80 |
PNEUMATOSIS INTESTINALIS |
1 |
0.0004 |
| 81 |
ENTEROCOLITIS |
2 |
0.0003 |
| 82 |
PENILE PAIN |
1 |
0.0003 |
| 83 |
INTRACARDIAC THROMBUS |
1 |
0.0003 |
| 84 |
BRAIN DEATH |
1 |
0.0003 |
| 85 |
INJECTION SITE HYPERSENSITIVITY |
1 |
0.0003 |
| 86 |
CORONAVIRUS INFECTION |
2 |
0.0003 |
| 87 |
ERYTHEMA NODOSUM |
1 |
0.0003 |
| 88 |
RETINAL HAEMORRHAGE |
2 |
0.0003 |
| 89 |
SKIN WEEPING |
1 |
0.0003 |
| 90 |
AMYLASE INCREASED |
1 |
0.0003 |
| 91 |
LEUKOENCEPHALOPATHY |
1 |
0.0003 |
| 92 |
LIPASE INCREASED |
2 |
0.0003 |
| 93 |
BRONCHOPULMONARY ASPERGILLOSIS |
2 |
0.0003 |
| 94 |
HAEMORRHAGIC STROKE |
2 |
0.0003 |
| 95 |
ANAPHYLACTIC REACTION |
14 |
0.0003 |
| 96 |
BACTERAEMIA |
3 |
0.0003 |
| 97 |
OESOPHAGEAL CANDIDIASIS |
1 |
0.0003 |
| 98 |
GROIN PAIN |
2 |
0.0002 |
| 99 |
CYTOMEGALOVIRUS VIRAEMIA |
1 |
0.0002 |
| 100 |
LOCALISED OEDEMA |
1 |
0.0002 |
| 101 |
INTERCEPTED MEDICATION ERROR |
1 |
0.0002 |
| 102 |
DISSEMINATED INTRAVASCULAR COAGULATION |
3 |
0.0002 |
| 103 |
SUBCUTANEOUS ABSCESS |
1 |
0.0002 |
| 104 |
ENTEROCOCCAL INFECTION |
1 |
0.0002 |
| 105 |
VITREOUS FLOATERS |
2 |
0.0002 |
| 106 |
HYPERVOLAEMIA |
1 |
0.0002 |
| 107 |
INJECTION SITE INFLAMMATION |
1 |
0.0002 |
| 108 |
PARTIAL SEIZURES |
1 |
0.0002 |
| 109 |
BLOOD TRIGLYCERIDES INCREASED |
3 |
0.0002 |
| 110 |
TYPE 1 DIABETES MELLITUS |
1 |
0.0002 |
| 111 |
BACTERIAL INFECTION |
3 |
0.0002 |
| 112 |
ENTERITIS |
1 |
0.0002 |
| 113 |
ASPERGILLUS INFECTION |
1 |
0.0002 |
| 114 |
CARDIAC FAILURE ACUTE |
1 |
0.0001 |
| 115 |
EYE HAEMORRHAGE |
2 |
0.0001 |
| 116 |
GENERAL PHYSICAL CONDITION ABNORMAL |
1 |
0.0001 |
| 117 |
INFARCTION |
1 |
0.0001 |
| 118 |
CEREBRAL DISORDER |
1 |
0.0001 |
| 119 |
ACIDOSIS |
1 |
0.0001 |
| 120 |
PULMONARY HAEMORRHAGE |
1 |
0.0001 |
| 121 |
PRODUCT ADMINISTRATION INTERRUPTED |
1 |
0.0001 |
| 122 |
ESCHERICHIA INFECTION |
1 |
0.0001 |
| 123 |
FACE OEDEMA |
2 |
0.0001 |
| 124 |
CANDIDA INFECTION |
2 |
0.0001 |
| 125 |
PRODUCT CONTAINER ISSUE |
1 |
0.0001 |
| 126 |
MUCOSAL INFLAMMATION |
3 |
0.0001 |
| 127 |
URTICARIA |
19 |
0.0001 |
| 128 |
PRODUCT COMMUNICATION ISSUE |
1 |
0.0001 |
| 129 |
HYPERSENSITIVITY |
21 |
0.0001 |
| 130 |
RESPIRATORY RATE INCREASED |
1 |
0.0001 |
| 131 |
MYOSITIS |
1 |
0.0001 |
| 132 |
NEUTROPENIA |
15 |
0.0001 |
| 133 |
LEUKAEMIA |
1 |
0.0001 |
| 134 |
MULTIPLE ORGAN DYSFUNCTION SYNDROME |
3 |
0.0001 |
| 135 |
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME |
1 |
0.0001 |
| 136 |
HYPOGLYCAEMIA |
5 |
0.0001 |
| 137 |
TRANSFUSION |
1 |
0.0001 |
| 138 |
CLOSTRIDIUM DIFFICILE COLITIS |
1 |
0.0001 |
| 139 |
VIRAL INFECTION |
3 |
0.0001 |
| 140 |
MALNUTRITION |
1 |
0.0001 |
| 141 |
THERAPEUTIC PRODUCT EFFECT DECREASED |
4 |
0.0001 |
| 142 |
LYMPHADENOPATHY |
3 |
0.0001 |
| 143 |
CYTOPENIA |
1 |
0.0001 |
| 144 |
ENCEPHALOPATHY |
2 |
0.0001 |
| 145 |
INTERCEPTED PRODUCT PREPARATION ERROR |
1 |
0.0001 |
| 146 |
ILEUS |
1 |
0.0001 |
| 147 |
HAEMATEMESIS |
2 |
0.0001 |
| 148 |
IMMUNE SYSTEM DISORDER |
1 |
0.0001 |
| 149 |
MENTAL STATUS CHANGES |
2 |
0.0001 |
| 150 |
HAEMORRHAGE INTRACRANIAL |
1 |
0.0001 |
| 151 |
RASH ERYTHEMATOUS |
3 |
0.0001 |
| 152 |
MANIA |
1 |
0.0001 |
| 153 |
GENERALISED TONIC-CLONIC SEIZURE |
1 |
0.0001 |
| 154 |
INCORRECT ROUTE OF PRODUCT ADMINISTRATION |
1 |
0.0001 |
| 155 |
HAEMORRHAGE |
6 |
0.0001 |
| 156 |
HYPERGLYCAEMIA |
2 |
0.0001 |
| 157 |
SEPSIS |
6 |
0.0001 |
| 158 |
HEPATIC STEATOSIS |
1 |
0.0001 |
| 159 |
PANCYTOPENIA |
3 |
0.0001 |
| 160 |
THROMBOCYTOPENIA |
6 |
0.0001 |
| 161 |
ORAL HERPES |
1 |
0.0001 |
| 162 |
FULL BLOOD COUNT DECREASED |
1 |
0.0000 |
| 163 |
PRODUCT PREPARATION ERROR |
1 |
0.0000 |
| 164 |
EATING DISORDER |
1 |
0.0000 |
| 165 |
LIVER FUNCTION TEST INCREASED |
1 |
0.0000 |
| 166 |
ALTERED STATE OF CONSCIOUSNESS |
1 |
0.0000 |
| 167 |
INCORRECT PRODUCT ADMINISTRATION DURATION |
1 |
0.0000 |
| 168 |
SEPTIC SHOCK |
2 |
0.0000 |
| 169 |
RASH PAPULAR |
1 |
0.0000 |
| 170 |
PANCREATITIS ACUTE |
1 |
0.0000 |
| 171 |
RASH |
18 |
0.0000 |
| 172 |
RESPIRATORY FAILURE |
3 |
0.0000 |
| 173 |
CEREBRAL INFARCTION |
1 |
0.0000 |
| 174 |
FLUSHING |
4 |
0.0000 |
| 175 |
HYPOPHAGIA |
1 |
0.0000 |
| 176 |
DRUG RESISTANCE |
1 |
0.0000 |
| 177 |
OFF LABEL USE |
33 |
0.0000 |
| 178 |
BLOOD BILIRUBIN INCREASED |
1 |
0.0000 |
| 179 |
PALLOR |
1 |
0.0000 |
| 180 |
CARDIAC ARREST |
3 |
0.0000 |
| 181 |
RESPIRATORY DISTRESS |
1 |
0.0000 |
| 182 |
VOMITING |
17 |
0.0000 |
| 183 |
BLOOD CREATINE PHOSPHOKINASE INCREASED |
1 |
0.0000 |
| 184 |
HEPATIC FAILURE |
1 |
0.0000 |
| 185 |
STOMATITIS |
2 |
0.0000 |
| 186 |
NAUSEA |
26 |
0.0000 |
| 187 |
INJECTION SITE RASH |
1 |
0.0000 |
| 188 |
ALANINE AMINOTRANSFERASE INCREASED |
2 |
0.0000 |
| 189 |
DRUG INTOLERANCE |
3 |
0.0000 |
| 190 |
STAPHYLOCOCCAL INFECTION |
1 |
0.0000 |
| 191 |
INFUSION RELATED REACTION |
2 |
0.0000 |
| 192 |
LIP SWELLING |
1 |
0.0000 |
| 193 |
FUNGAL INFECTION |
1 |
0.0000 |
| 194 |
URINARY RETENTION |
1 |
0.0000 |
| 195 |
INJECTION SITE REACTION |
2 |
0.0000 |
| 196 |
BURNING SENSATION |
2 |
0.0000 |
| 197 |
PLATELET COUNT DECREASED |
3 |
0.0000 |
| 198 |
ELECTROCARDIOGRAM QT PROLONGED |
1 |
0.0000 |
| 199 |
UNDERDOSE |
2 |
0.0000 |
| 200 |
AGITATION |
2 |
0.0000 |
| 201 |
INJECTION SITE MASS |
1 |
0.0000 |
| 202 |
HEPATIC FUNCTION ABNORMAL |
1 |
0.0000 |
| 203 |
UNEVALUABLE EVENT |
2 |
0.0000 |
| 204 |
PYREXIA |
9 |
0.0000 |
| 205 |
SEIZURE |
3 |
0.0000 |
| 206 |
DECREASED APPETITE |
6 |
0.0000 |
| 207 |
CARDIAC FAILURE |
2 |
0.0000 |
| 208 |
DYSKINESIA |
1 |
0.0000 |
| 209 |
NEUTROPHIL COUNT DECREASED |
1 |
0.0000 |
| 210 |
PRODUCT STORAGE ERROR |
2 |
0.0000 |
| 211 |
DEHYDRATION |
3 |
0.0000 |
| 212 |
VISION BLURRED |
3 |
0.0000 |
| 213 |
INFECTION |
3 |
0.0000 |
| 214 |
SYNCOPE |
2 |
0.0000 |
| 215 |
CELLULITIS |
1 |
0.0000 |
| 216 |
THERAPY CESSATION |
1 |
0.0000 |
| 217 |
ILLNESS |
2 |
0.0000 |
| 218 |
INFLAMMATION |
1 |
0.0000 |
| 219 |
MUSCULOSKELETAL PAIN |
1 |
0.0000 |
| 220 |
ASPARTATE AMINOTRANSFERASE INCREASED |
1 |
0.0000 |
| 221 |
CONFUSIONAL STATE |
3 |
0.0000 |
| 222 |
MEDICATION ERROR |
1 |
0.0000 |
| 223 |
NECK PAIN |
1 |
0.0000 |
| 224 |
OXYGEN SATURATION DECREASED |
1 |
0.0000 |
| 225 |
EYE PAIN |
1 |
0.0000 |
| 226 |
LETHARGY |
1 |
0.0000 |
| 227 |
BONE PAIN |
1 |
0.0000 |
| 228 |
PAIN IN EXTREMITY |
5 |
0.0000 |
| 229 |
DISEASE PROGRESSION |
2 |
0.0000 |
| 230 |
WHEEZING |
1 |
0.0000 |
| 231 |
PLEURAL EFFUSION |
1 |
0.0000 |
| 232 |
ANAEMIA |
3 |
0.0000 |
| 233 |
HYPERHIDROSIS |
2 |
0.0000 |
| 234 |
PRODUCT QUALITY ISSUE |
2 |
0.0000 |
| 235 |
HEPATIC ENZYME INCREASED |
1 |
0.0000 |
| 236 |
SKIN BURNING SENSATION |
1 |
0.0000 |
| 237 |
MOBILITY DECREASED |
1 |
0.0000 |
| 238 |
HALLUCINATION |
1 |
0.0000 |
| 239 |
ACUTE KIDNEY INJURY |
2 |
0.0000 |
| 240 |
INJECTION SITE PAIN |
4 |
0.0000 |
| 241 |
HOSPITALISATION |
2 |
0.0000 |
| 242 |
TOXICITY TO VARIOUS AGENTS |
2 |
0.0000 |
| 243 |
CEREBROVASCULAR ACCIDENT |
2 |
0.0000 |
| 244 |
MYALGIA |
2 |
0.0000 |
| 245 |
TACHYCARDIA |
1 |
0.0000 |
| 246 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
2 |
0.0000 |
| 247 |
COUGH |
3 |
0.0000 |
| 248 |
PULMONARY EMBOLISM |
1 |
0.0000 |
| 249 |
NEUROPATHY PERIPHERAL |
1 |
0.0000 |
| 250 |
CONTUSION |
1 |
0.0000 |
| 251 |
PRODUCT DOSE OMISSION ISSUE |
3 |
0.0000 |
| 252 |
MALIGNANT NEOPLASM PROGRESSION |
1 |
0.0000 |
| 253 |
HAEMOGLOBIN DECREASED |
1 |
0.0000 |
| 254 |
ERYTHEMA |
2 |
0.0000 |
| 255 |
HEADACHE |
6 |
0.0000 |
| 256 |
HYPERTENSION |
2 |
0.0000 |
| 257 |
PNEUMONIA |
3 |
0.0000 |
| 258 |
FATIGUE |
7 |
0.0000 |
| 259 |
MUSCULAR WEAKNESS |
1 |
0.0000 |
| 260 |
INCORRECT DOSE ADMINISTERED |
2 |
0.0000 |
| 261 |
ABDOMINAL PAIN |
2 |
0.0000 |
| 262 |
INJECTION SITE ERYTHEMA |
1 |
0.0000 |
| 263 |
PRURITUS |
3 |
0.0000 |
| 264 |
DEATH |
6 |
0.0000 |
| 265 |
BLOOD PRESSURE INCREASED |
1 |
0.0000 |
| 266 |
DIARRHOEA |
4 |
0.0000 |
| 267 |
TREMOR |
1 |
0.0000 |
| 268 |
ABDOMINAL DISCOMFORT |
1 |
0.0000 |
| 269 |
COVID-19 |
1 |
0.0000 |
| 270 |
CHEST PAIN |
1 |
0.0000 |
| 271 |
ASTHENIA |
2 |
0.0000 |
| 272 |
BLOOD GLUCOSE INCREASED |
1 |
0.0000 |
| 273 |
DYSPNOEA |
3 |
0.0000 |
| 274 |
GAIT DISTURBANCE |
1 |
0.0000 |
| 275 |
HYPOTENSION |
1 |
0.0000 |
| 276 |
SOMNOLENCE |
1 |
0.0000 |
| 277 |
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS |
1 |
0.0000 |
| 278 |
ABDOMINAL PAIN UPPER |
1 |
0.0000 |
| 279 |
ARTHRALGIA |
2 |
0.0000 |
| 280 |
CONSTIPATION |
1 |
0.0000 |
| 281 |
BACK PAIN |
1 |
0.0000 |
| 282 |
PRODUCT USE IN UNAPPROVED INDICATION |
1 |
0.0000 |
| 283 |
CONDITION AGGRAVATED |
1 |
0.0000 |
| 284 |
PAIN |
2 |
0.0000 |
| 285 |
MALAISE |
1 |
0.0000 |
| 286 |
DRUG INEFFECTIVE |
3 |
0.0000 |
| 287 |
DIZZINESS |
1 |
0.0000 |